RSI spoločnosti NeuroVive Pharmaceutical AB
Aká je hodnota metriky RSI spoločnosti NeuroVive Pharmaceutical AB?
Hodnota metriky RSI spoločnosti NeuroVive Pharmaceutical AB je 5.26
Aká je definícia metriky RSI?
Index relatívnej sily (Relative strength index - RSI 14) je technický ukazovateľ, ktorý sa radí medzi momentum indikátory a meria rýchlosť a zmenu ceny. Jeho hodnota sa pohybuje medzi 0 a 100 a používa sa na charakterizovanie prekupovaného a prepredaného stavu.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI spoločností v sektore Health Care sektor na OTC v porovnaní so spoločnosťou NeuroVive Pharmaceutical AB
Čomu sa venuje spoločnosť NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Firmy s metrikou rsi podobnou spoločnosti NeuroVive Pharmaceutical AB
- Hodnota metriky RSI spoločnosti IRC je 5.17
- Hodnota metriky RSI spoločnosti Huazhong In-Vehicle je 5.18
- Hodnota metriky RSI spoločnosti Cello Health plc je 5.18
- Hodnota metriky RSI spoločnosti Transmetro je 5.22
- Hodnota metriky RSI spoločnosti Voestalpine AG je 5.24
- Hodnota metriky RSI spoločnosti Baru Gold Corp je 5.24
- Hodnota metriky RSI spoločnosti NeuroVive Pharmaceutical AB je 5.26
- Hodnota metriky RSI spoločnosti Aloro Mining je 5.32
- Hodnota metriky RSI spoločnosti Pilot je 5.32
- Hodnota metriky RSI spoločnosti Cpl Resources plc je 5.34
- Hodnota metriky RSI spoločnosti Supreme Metals Corp je 5.36
- Hodnota metriky RSI spoločnosti Baring Emerging Europe Plc je 5.37
- Hodnota metriky RSI spoločnosti Waseco Resources je 5.39